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INTRODUCTION 
 
 Chronic liver disease is a pathologically defined entity which is 
associated with a spectrum of characteristic clinical manifestations.   The   
cardinal pathologic   features reflect irreversible chronic injury to the hepatic 
parenchyma and include extensive fibrosis in association with formation of 
regenerative nodules.  These   features  result   from   hepatocyte necrosis,  
collapse  of  the  supporting reticular  network  with subsequent connective 
tissue deposition,  distortion  of  the vascular  bed,  and nodular regeneration  
of  remaining  liver  parenchyma most common causes of chronic liver 
disease in general order of frequency are chronic hepatitis C, alcoholic liver 
disease, non alcoholic steatohepatitis. Chronic hepatitis B, autoimmune 
hepatitis, sclerosing cholangitis, primary biliary cirrhosis, haemochromatosis 
and Wilson‟sdisease. These chronic liver disease ultimately develop 
cirrhosis. 
Chronic Liver Disease includes chronic hepatitis and cirrhosis. 
Chronic hepatitis eventually leads to cirrhosis. Cirrhosis, the end result of all 
chronic liver disease is, characterized by diffuse destruction and regeneration 
of hepatic parenchymal cells leading to deposition of connective tissue with 
resulting disorganization of the lobular and vascular architecture. In spite of 
the remarkable regenerative capacity of the liver, once hepatic parenchymal  
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reserve is  exceeded,  clinically overt  or decompensated chronic liver 
disease ensues. Portal hypertension develops due to resistance to blood flow 
through the liver resulting increase in portal venous pressure leading to 
diversion of blood flow through low resistance portosystemic collaterals 
thereby bypassing the liver.  
Liver cirrhosis is associated with a range of cardiovascular 
abnormalities. This was first described by Kowalski and Abelmann who 
noted a higher resting cardiac output and decreased systemic vascular 
resistance in patients with cirrhosis
1, 2
. However, despite the hyperdynamic 
circulation, impaired ventricular contractility in response to stimuli was 
described in cirrhotic patients
3-7
. These abnormalities were initially thought 
to be a manifestation of latent alcoholic cardiomyopathy. But in the mid 
1980s, studies in nonalcoholic patients and in experimental animal models 
showed a similar pattern of blunted cardiac contractile responsiveness
8-10
. 
Thus these cardiovascular changes are now termed „Cirrhotic 
cardiomyopathy‟11-14. 
The prevalence of cirrhotic cardiomyopathy remains unknown at 
present. Features include structural, histological, electrophysiological, 
systolic and diastolic dysfunction. Multiple factors are considered as 
responsible, including impaired beta-adrenergic receptor signal transduction, 
abnormal membrane biophysical characteristics, and increased activity of 
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cardiodepressant systems mediated by cGMP
15
. 
Overt heart failure is not generally a feature of cirrhotic 
cardiomyopathy, because the associated marked vasodilatation 
accompanying the hyperdynamic circulation significantly reduces ventricular 
afterload. However, major stresses on the cardiovascular system such as liver 
transplantation, infections and insertion of transjugular intrahepatic 
portosystemic shunts (TIPS) can unmask the presence of cirrhotic 
cardiomyopathy and thereby convert latent to overt heart failure. Cirrhotic 
cardiomyopathy may also contribute to the pathogenesis of hepatorenal 
syndrome and circulatory failure in liver cirrhosis
15
. 
Diastolic dysfunction is present in the vast majority of patients with 
cirrhotic cardiomyopathy, and that simple echocardiographic indices such as 
the E/A ratio may detect diastolic dysfunction even at rest. This may 
therefore represent the best available screening test to diagnose cardiac 
dysfunction
16
.  
Due to the limited number of human studies, the management of 
cirrhotic cardiomyopathy remains largely empirical. Treatment of this 
condition is mainly supportive. Orthotropic liver transplantation appears to 
improve or normalize the condition, generally after a period of several 
months
17
. If overt heart failure develops in these patients, then the same 
general treatment principles of noncirrhotic congestive heart failure apply, 
  
9 
including bed rest, salt restriction, oxygen, diuretics, and careful preload and 
afterload reduction
14
. 
The  current   study  was  designed  to   precisely  evaluate  the 
cardiovascular system in a group  of patients  with  chronic  liver disease-
cirrhosis based on clinical examination, elctrocardiography, 
roentgenography  and M-Mode  2-dimensional  echocardiography. 
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AIM OF THE STUDY 
 
1. To clinically  evaluate patients  with  chronic liver disease with respect  
to changes  in  heart rate,  blood pressure,  mean  arterial pressure,  
jugular venous  pressure and  precordial  examination.  
 
2. To document the electrical and morphological alterations in  the  heart  
in patients with chronic liver disease  by means of  non-invasive  
investigations like  electrocardiography,  roentghenography  and  M-
Mode 2-Dimensional echocardiography. 
  
3. To determine the  relationship between the  cardiac  and   
hemodynamic parameters  and  the  severity and  extent  of  chronic  
liver  disease. 
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REVIEW OF LITERATURE 
  
Liver diseases may be acute or chronic. Most common causes of 
chronic liver disease in general order of frequency are chronic hepatitis C, 
alcoholic liver disease, non alcoholic steatohepatitis. Chronic hepatitis B, 
autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, 
haemochromatosis and Wilson‟s disease. These chronic liver disease 
ultimately develop cirrhosis. 
Chronic liver disease is a pathologically defined entity which is 
associated with a spectrum of characteristic clinical manifestations.   The   
cardinal pathologic   features  reflect  irreversible  chronic injury  to  the  
hepatic parenchyma and include extensive fibrosis in association with  
formation  of regenerative  nodules (fig;1).  These   features  result   from   
hepatocyte necrosis,  collapse  of  the  supporting reticular  network  with 
subsequent connective tissue deposition,  distortion  of  the vascular  bed,  
and nodular regeneration  of  remaining  liver  parenchyma.  Despite the 
remarkable regenerative capacity of the liver, once the hepatic parenchymal 
reserve is exceeded, clinically overt or decompensated cirrhosis ensues. 
Classification of Chronic liver disease 
1. Chronic Hepatitis 
2. Cirrhosis 
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 1. Chronic Hepatitis  
a) Chronic persistent hepatitis  
b) Chronic active hepatitis  
c) Chronic lobular hepatitis  
Causes of chronic hepatitis  
Chronic hepatitis B 
Chronic hepatitis B Plus D 
Chronic hepatitis C 
Autoimmune hepatitis  
Drug related chronic hepatitis  
Alcoholic hepatitis  
Non alcoholic steatohepatitis  
Metabolic causes (Primary billiary cirrhosis, sclerosing cholangitis 
wilson‟s disease, haemochromatosis) cryptogenic chronic hepatitis.  
Microscopic appearance    
Periportal necrosis including piecemeal necrosis and bridging necrosis  
Intralobular necrosis  
Portal inflammation  
Fibrosis  
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2. Cirrhosis  
a) Micro – Nodular cirrhosis 
b) Macro –Nodular Cirrhosis  
c) Mixed cirrhosis.  
 
Cirrhosis Classification: 
1. Micro nodular cirrhosis: There is preponderance of parenchymal 
nodules that are less than 3 mm in diameter. There is involvement of 
every lobule.  The micro nodular liver may represent impaired 
capacity   for regrowth as in alcoholism, malnutrition, old age and 
anaemia. 
 
2. Macro nodular cirrhosis: In this size of the nodules exceed more than 
3 mm in diameter. Nodules are highly variable is size and normal 
lobules are found amongst larger nodules.  Regeneration  is reflected  
by  large  cells  with large  nuclei and  by cell  plates  of varying  
thickness  eg. Post necrotic cirrhosis. 
 
3. Mixed Cirrhosis:  Combination of micro nodules and   macro nodules 
eg.  Biliary cirrhosis. 
Most types of cirrhosis may  be  conveniently  classified  by  a mixture 
of  etiologically  and   morphologically  defined  entities  as   follows. 
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1. Alcoholic 
2. Cryptogenic 
3. Post viral or post necrotic  
 Viral hepatitis [Hepatitis B, Non – A, Non – B] 
 Hepatitis D, hepatitis C, Cytomegalovirus 
 Toxoplasmosis 
 Schistosomiasis 
 Ecchinococcus 
 Brucellosis 
4. Inherited and Metabolic disorders : 
 Haemochromatosis  
 Wilson‟s disease  
 Alpha 1 – antitrypsin deficiency   
 Galactosaemia 
 Glycogen storage disease 
 Gaucher‟s disease 
 Hereditary fructose intolerance  
 Hereditary tyrosinemia  
 Fanconi‟s syndrome 
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5. Drugs and toxins : 
 Methyldopa  
 Methotrexate 
 Isoniazid  
 Perhexilene maleate 
 Oxyphenisatin 
 Arsenicals  
 Oxyphenisatin 
 Arsenicals 
6. Biliary Cirrhosis :  
 Primary 
 Secondary 
 Hepatic venous outflow obstruction : 
 Budd Chiari Syndrome 
 Cardiac cirrhosis 
 Veno occlusive disease 
7. Miscellaneous: 
 Sarcoidosis 
 Graft Vs Host disease  
 Chronic inflammatory bowel disease 
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 Cystic fibrosis 
 Jejunoileal bypass 
 Diabetes mellitus  
 Carcinomatous cirrhosis 
 Indian childhood cirrhosis 
 Immunological – Lupoid hepatitis.  
Clinical and Biochemical Classification: 
Clinical features of  cirrhosis (fig :2)  derive  from  the  morphologic 
alterations and often reflect the  severity of  liver damage  rather  than  the 
etiology of  underlying  liver  disease. Loss of  functioning  hepatocellular 
mass  may  lead to  jaundice,  edema,  coagulopathy,  spider telangiectasia, 
palmar erythema , parotid  and  lacrimal gland  enlargement , nail  changes, 
Dupuytren contractures,  gynaecomastia,  ascites,  testicular  atrophy as  well  
as  confusion  and   asterexis  suggesting   hepatic  encephalopathy.  
Distorted   vasculature leads to portal   hypertension.   Portal 
hypertension  develops  when  resistance to blood flow through  the liver, is 
increased  and  resulting  increase  in  portal  venous  pressure  lead  to 
diversion of  blood flow  through  low resistance  portosystemic  collaterals 
thereby  bypassing  the  liver.  Hyperdynamic  circulation,  caput medusae, 
splenomegaly  and  gastro esophageal  varices  more  directly  suggest  the 
presence  of  portal hypertention. 
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          Fig.1.FIBROSIS WITH NODULAR REGENERATION 
 
 
 
 
 
 
 
 
 
 
Fig.2.CLINICAL FEATURES OF CIRRHOSIS 
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Ascites and hepatic encephalopathy result from both hepatocellular 
insufficiency and portal hypertension.  
Compensated Cirrhosis: 
This stage is discovered by the following 
a) Early symptoms:  
 Vague abdominal pain 
 Fatigue  
 Mild pyrexia  
 Vascular spiders  (fig : 3) 
 Palmar erythema (fig : 4)  
 Unexplained epistaxis  
 Ankle oedema  
b) Detected on a routine check up 
 Firm non tender hepatosplenomegaly (fig : 5) 
 Elevated transaminases 
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Fig: 3 VASCULAR SPIDERS AND METHOD OF DEMONSTRAITON 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4  PALMAR ERYTHEMA 
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c) Background 
 Alcoholism  
 Hepatitis 
 Decompensated Cirrhosis   
The patient usually seeks medical advice because of ascites and/or 
jaundice. Features include poor general health, muscle wasting, weight loss. 
(fig: 6): Continuous  mild  fever (37.5 – 38
0
C)  is often due to gram negative    
bacteremia., to continuing  hepatic  cell  necrosis  or  to  a complicating  liver  
cell carcinoma. Foetor hepaticus may be present. Cirrhosis is the commonest 
cause of hepatic encephalopathy.  
Jaundice (fig : 7 ) implies  that  liver  cell  destruction  exceeds   the 
capacity  of  regeneration and deeper the jaundice, greater  the  inadequacy 
of the  liver cell  function. 
The skin may be pigmented. Clubbing of fingers may be present. 
Purpura over the arms, shoulders and shins may be associated with a low 
platelet count. Spontaneous bruising and epistaxis reflect a prothrombin 
deficiency.   
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FIG 5: SPLENOMEGALY 
 
FIG : 6 : DECOMPENSATED CIRRHOSIS 
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The circulation is overactive.  The blood pressure is low.  Sparse body  
hair,  vascular  spiders,  palmar erythema,  white  nails (Leuconychia) and  
gonadal  atrophy  are  common.  
 
Ascites is usually preceded by abdominal distention edema of the legs 
is frequently seen (fig: 8) 
 
The liver may be enlarged and firm or contracted and impalpable. 
Spleen may be palpable and firm. Haemetological manifestations of 
Cirrhosis include anemia, leukopenia and thrombocytopenia which may 
result from splenomegaly and hypersplenism. Clotting factor abnormalities 
also seen. 
A classification scheme based on a combination of several factors, the 
Child-Turcotte classification has been useful in estimating long term 
outcome which is represented below. 
CHILD TURCOTTE CLASSIFICATION OF SEVERITY OF 
CIRRHOSIS 
INDEX  CLASS  
 A B C 
Bilirubin (mg/dl) <2.0 2.0-3.0 >3.0 
Albumin (g/dl)  >3.5 3-3.5 <3 
Ascites None Easily controlled Poorly Controlled 
Encephalopathy None Mild Advanced 
Nutritional Status Excellent Good Poor 
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FIG : 7 :  JAUNDICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG: 8 :  ASCITES WITH EDEMA LEGS 
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PATHOPHYSIOLOGY OF PORTAL HYPERTENSION: 
The   fundamental hemodynamic   abnormality is an increased 
resistance to portal blood flow. This may be intra hepatic as in cirrhosis or 
due to obstructed portal vein due to thrombosis. As  the  portal  venous 
pressure is lowered  by  the  development  of  collaterals  deviating  portal 
blood  into  systemic  veins,  the  portal  hypertention  is  maintained  by 
increasing  the  blood  flow  in  the  portal  system which  thus  becomes 
hyperdynamic.  Resistance  to portal blood  flow  is exerted  along both the 
hepatic and  portal  collateral  circulation  and  appears  to be modified by 
vasoactive  agents.  Portal hypertension is defined as portal venous pressure 
exceeding 12 mm Hg. 
ROLE OF ULTRASOUND: 
Ultrasonography has proved to be a useful non invasive   and 
inexpensive method to establish the presence of and aetiology of portal 
hypertension.  
A normal ultrasound shows the liver to have mixed echogenicity.  In 
cirrhosis  of  the liver  the edge of  the  liver may be irregular and  the liver 
shows  coarse  echo  pattern. It has a fine stippled echogenicity due to 
increased acoustic attenuation.  In end stage cirrhosis the liver is small and 
very echogenic. It has a nodular border and may be outlined well by ascitic 
fluid. One portion of the liver may have a different echogenicity from the 
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remainder and form a bulge.  This represents a regenerating nodule. Portal 
hypertension and splenomegarly are present.  Caudate lobe is enlarged 
relative to the right lobe.  
The presence of portal hypertension is sonologically assessed by the 
following features.  
1. Splenomegaly : If  the  transducer  has  a  90
0
  angle  and  the superior  
and  inferior  border  of  the spleen cannot  fit on an image, the spleen 
is  enlarged. Static scans are helpful if serial exams for splenomegaly 
are needed. To evaluate splenic size on a static scan a superior view is 
preferred.  The  spleen  is  enlarged  when  its anterior border lies in 
front  of  the aorta and  inferior vena cava and it is  at  least  as  thick  
as  a  normal  kidney. 
2. Portal vein dilated to >1.3cm. Estimation of  portal  vein and  splenic 
vein  diameter  is  useful  to  predict  the  presence  of  oesophageal 
varices. Portal vein  and  splenic vein  size of  12 mm  8 mm  are good 
predictors  ( 93.05%   and  94.89%  respectively  )  of    oesophageal 
varices  but  their size did not  differ significantly according  to grade 
of varices.  
 
  
26 
 
FIG:  9: COLLARERALS OVER THE ANTERIOR 
ABDOMINAL WALL 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG:  9 (a) Liver Biopsy 
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3. Recanalization of paraumbilical veins with in the ligamentum teres. 
4. Collaterals – Small  tortuous  vessels  at  porta hepatis  gastric fundus, 
pancreatic  beds  splenic  hilum – Doppler  and  colour  flow  detect 
vessels.  
5. Dilated splenic and superior mesenteric veins. 
6. Ascites 
7. Normal flow in the portal vein and hepatic artery is in the direction to 
the liver – Hepatopetal.  In  severe portal  hypertension  flow  in  the 
portal  vein  is  reversed  towards  the  feet – hepatofugal. Colour  flow 
makes  this change is direction obvious  and  Doppler  cursor  through 
both  vessels  simultaneously  demonstrates  the  direction  of   flow. 
8. Fenestrated thickened gall bladder wall is a unique Ultrasonagraphic 
sign seen in patients with portal hypertention. This appearance  is   
possible  due  to  congestive   thickness  of  the  gall  bladder wall  
with  collaterals  in  the  wall  giving  it  a  fenestrated appearance. 
ROLE OF ABDOMINAL PARACENTESIS:  
Diagnostic paracentesis of about 50 ml is always performed in case of 
ascites. Complication like bowel  perforation and  hemorrhage  may  rarely 
occurs in  patients  with  cirrhosis  of  liver after  paracentesis. 
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Protein concentration rarely exceeds 2.5 g/100 ml.  Higher values 
suggest infection. If serum albumin to ascites albumin gradient (SAAG) is 
greater than 1.1 g/dl then it indicates presence of portal hypertension. The 
SAAG reflects a difference in the oncotic pressures and correlates well with 
the portal venous pressure.  
Fluid  usually  appears  straw  coloured  or  clear and  sometimes in 
advanced  cirrhosis  chylous  ascites may  result due  to  accumulation  of 
chylomicrons  in  the  ascitic  fluid.  
From 1950 onwards abdominal paracentesis was the accepted 
Treatment   of tense ascites. Selection criteria for the therapeutic paracentesis   
include.  
 Tense ascites preferably with edema  
 Child‟s grade B 
 Prothrombin > 40 %  
 Serum Bilirubin <10 mg/dl 
 Platelets > 40,000/cu mm  
 Serum creatinine<3 mg /dl  
 Urinary sodium>10 mEq/24 hrs 
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Usually 5-10 litres of fluid is removed followed by replacement of salt 
poor albumin 1V 6g/litre of fluid removed. Single large paracentesis of about 
10 L in 1 hour with intravenous salt poor albumin is also equally effective 
and safe. 
ROLE OF LIVER BIOPSY: 
Needle Biopsy of The liver:  
Needle biopsy of the liver is indicated in the cirrhosis of liver in that it 
helps to confirm the diagnosis and may provide a clue for the aetiology of 
cirrhosis. Since  the  lesions  in most cases  of  cirrhosis liver are diffuse,  
such  a small  biopsy  specimen  is  representive of  changes  in the  whole 
liver. 
The exception to this is macro nodular cirrhosis in which aspiration 
often large nodule may reveal normal architecture. The diagnostic  yield may  
be  improved by  three consecutive  samples  obtained  by  redirecting the  
biopsy  needle. 
Types of needles used: 
 Vim Silverman Needle 
 Menghini Needle 
Trucut needle: For the purpose of the study, the trucut needle was 
chosen because it is of value in cirrhosis patients as   it caused less 
fragmentation. 
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Biopsy gun (BIOPTER)  
Surecut needle:  0.66 mm, may be used to diagnose cirrhosis when the 
Menghini needle is contraindicated. Risk of complication is minimal.  
Approach For liver Biopsy: 
1. Intercostal approach is the most frequent method and it rarely fails. 
2. Liver biopsy  can  also be  performed  via  the transjugular  route  in 
patient  with  small  liver,  failed transcutaneous  approach.  Wedged 
and free hepatic venous pressure can be measured simultaneously. 
3. Direct (Guided) liver Biopsy 
4. Ultrasound  or  CT  Scan   guided  liver  biopsies  give  a  higher 
percentage  of  positivity  than  the  blind  percutaneous  techniques. 
Contraindications: 
 Coagulation defects 
 Platelet count less than 80,000/cu mm  
 Tense ascites 
 Very  small fibrotic liver  
 Known vascular lesions like hemangioma 
Naked Eye Appearance: 
A satisfactory biopsy is 1-4 cms long and weighs 10-50 mg.  The 
cirrhotic liver tends to crumble into fragments of irregular contour.  
The biopsy is usually fixed in 10% formal – saline. Routine stains 
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include haematoxylin and eosin and a good stain for connective tissue. 
Orcein staining is useful  to show  hepatitis B surface antigen in the  
hepatocyte; and is also  an  indicator  of  cholestasis  and  Wilson‟s disease. 
Microscopic Appearance: 
This is characterized by the following : (Fig. 9 (a)) 
 Parenchymal  injury  and  consequent  diffuse fibrosis in  the  form 
of delicate  bands  ( portal  central,  portal-portal,  central – central) 
or broad  scars  replacing  multiple  adjacent  lobule. 
 Reorganized vascular architecture.  
 Parenchymal nodules created by regeneration of hepatocytes.  
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PATHOPHYSIOLOGY OF CARDIAC AND 
CIRCULATORY CHANGES IN CHRONIC LIVER 
DISEASE  
CHAMBER DYNAMICS AND MYOCARDIAL FUNCTION 
Chronic liver diseases like cirrhosis produce high cardiac output 
states. The mechanisms  is uncertain  but  has  been attributed  to  increased 
blood volume, intrahepatic  arteriovenous  shunts,  mesenteric  arteriovenous 
shunts  and  defects in  inactivation  of  circulating  vasodilators. 
M-Mode 2-Dimenisonal echocardiograph is a useful – invasive 
method of studying the various morphological and functional parameter. In 
patients with cirrhosis liver prior studies have shown that right ventricular 
end diastolic volume and right ventricular end systolic volume where 
significantly reduced in patients whereas left ventricular end diastolic 
volume and left ventricular end systolic volume and left atrial volume were 
normal or slightly increased. The right  ejection fraction was  significantly 
increased  and  the  left  ejection  fraction  was  slightly  decreased. There is 
also evidence of myocardial contractile function impairment and ventricular 
hyporesponsiveness to pharmacological or physiological stress. Diastolic 
dysfunction was found to be 35% in prior studies and more common in 
alcoholic than in non alcoholics.  These changes are reversed following liver 
transplantation. 
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Pericardial effusion has been demonstrated in a significant number of 
patients and is seen as echo free zone surrounding the heart and if large the 
whole heart can be seen swinging in to it. Pulmonary hypertension was seen 
in 12% of patients. 
The  incidence  of  coronary  and  aortic  atheroma  is  less than  the  
rest of  the population. At  autopsy, the  incidence  of  myocardial  infarction  
is about a quarter  of  that  among  total  cases  examined   without  cirrhosis. 
HAEMODYNAMIC CHANGES; 
Peripheral Vasodilatation and Hyperkinetic Systemic Circulation: 
Vasodilatation is characteristically shown by flushed extremities, 
bounding pulses and capillary pulsations. 
The cardiac output is raised and this is evidence by resting tachycardia 
and active precordial impulse and frequent systolic murmur. The splenic 
blood flow is increased. The renal blood flow especially renal cortical 
perfusion is reduced. Cutaneous micro circulation is reduced due to opening 
of arterio venous channels and neurohumoral factors. The cardiac index was 
significantly raised. 
The mean arterial pressure and peripheral resistance are markedly 
reduced. The blood pressure is further lowered and is an ominous sign as it 
further reduces kidney function.  
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Hemodynamic changes in cirrhosis 
Portal hypertension is one of the salient features of cirrhosis. Cirrhosis 
of the liver accounts for approximately 90% of cases of portal hypertension. 
Portal hypertension is a common clinical syndrome defined by a pathologic 
increase of portal venous pressure. As a consequence, the gradient between 
portal pressure (PP) and inferior vena cava pressure (IVC) (portal pressure 
gradient, PPG) is increased above the upper normal value of 5 mm Hg. The 
importance of portal hypertensive syndrome is defined by the frequency and 
severity of its complications, including upper gastrointestinal bleeding from 
ruptured gastroesophageal varices, ascites, and hepatorenal Syndrome, which 
represent the leading causes of death and of liver transplantation in patients 
with cirrhosis.  
Portal hypertension is considered to be clinically significant (CSPH) 
when PPG, or its clinical equivalent hepatic venous pressure gradient 
(HVPG), exceeds 10 to 12 mm Hg, since this is the threshold for the clinical 
manifestations of portal hypertensive syndrome to appear. The vast majority 
of patients with cirrhosis develop CSPH along the course of the disease, and 
data from a recent multicentric study indicate that CSPH is already present at 
diagnosis in approximately 60% of histologically proven, well-compensated 
cirrhosis case. 
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Portal hypertension is related both to vascular resistance and to portal 
blood flow.  The fundamental hemodynamic abnormality is an increased 
resistance to portal flow. This may be mechanical due to the disturbed 
architecture and nodularity of cirrhosis or due to an obstructed portal vein. 
Other intra-hepatic factors such as collagenosis of the space of Disse, 
hepatocyte swelling and the resistance offered by portal-systemic collaterals 
contribute. There is also a dynamic increase in intra-hepatic vascular 
resistance. 
Stellate (Ito) cells have contractile properties that can be modulated by 
vaso-active substances. These include nitric oxide (NO) which is 
vasodilatory and endothelin which is a vaso-constrictor. These may modulate 
intra-hepatic resistance and blood flow especially at a sinusoidal level. As 
the portal venous pressure is lowered by the development of collaterals 
deviating portal blood into systemic veins, portal hypertension is maintained 
by increasing portal flow in the portal system which becomes hyperdynamic. 
It is uncertain whether the hyperdynamic circulation is the cause or the 
consequence of the portal hypertension or both. It is related to the severity of 
liver failure. Cardiac output increases and there is generalized vasodilatation. 
Arterial blood pressure is normal or low. Splanchnic vasodilatation is 
probably the most important factor in maintaining the hyperdynamic 
circulation. Azygous blood flow is increased.  
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The increased portal flow raises the oesophageal variceal transmural 
pressure. The increased flow refers to total portal flow (hepatic and 
collaterals). The actual portal flow reaching the liver is, of course, reduced. 
The factors maintaining the hyperdynamic splanchnic circulation are 
multiple. There seems to be interplay of vasodilators and vaso-constrictors. 
These might be formed by the hepatocyte, fail to be inactivated by it or be of 
gut origin and pass through intra-hepatic or extra-hepatic venous shunts. 
Endotoxins and cytokines, largely formed in the gut, are important triggers. 
NO and endothelin-1 are synthesized by vascular endothelium in 
response to endotoxin. Prostacyclin is produced by portal vein endothelium 
and is a potent vasodilator. It may play a major role in the circulatory 
changes of portal hypertension due to chronic liver disease. Glucagon is 
vasodilatory after pharmacological doses but does not seem to be vaso-active 
at physiological doses. It is probably not a primary factor in the maintenance 
of the hyperkinetic circulation in established liver disease. 
Cardiac and vascular changes in cirrhosis 
The cardiovascular system in patients with cirrhosis or portal 
hypertension is abnormal. The circulation becomes hyperdynamic, 
characterized by increased cardiac output and decreased peripheral vascular 
resistance and arterial pressure. Moreover, despite the increased cardiac 
output at rest, with stressful stimuli such as hemorrhage, surgery or 
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vasoactive drug administration, the ventricular response is blunted, a 
condition known as cirrhotic cardiomyopathy. These cardiovascular 
abnormalities have been suggested to induce or aggravate several 
complications of cirrhosis such as renal salt and water retention, variceal 
bleeding, hepatopulmonary syndrome, and increased cardiovascular fragility 
under stress. Recent reviews have detailed the clinical aspects of 
hyperdynamic circulation
18, 19
 and cirrhotic cardiomyopathy
20, 21, 22.
 
HYPERDYNAMIC CIRCULATION 
Peripheral vasodilatation is central to hyperdynamic circulation and 
portal hypertension in cirrhosis. However, the factors directly initiating 
vasodilatation remain obscure. A hypothesis that has received much attention 
over the past three decades is the “humoral factor” theory. In cirrhosis, 
increased intrahepatic resistance induces portosystemic collateral formation, 
allowing gut-derived humoral substances to directly enter the systemic 
circulation without detoxification by the liver. The following gut-derived or 
locally-produced humoral factors have been implicated as possible mediators 
of peripheral vasodilatation in cirrhosis or portal hypertension. 
Endocannabinoids 
Endocannabinoids are lipid-like substances that act on two inhibitory 
G protein-coupled receptors, CB1 and CB2. The vasodilatory effect of 
endogenous cannabinoids in cirrhosis was first reported in 2001
23
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Anandamide, an endogenous cannabinoid or endocannabinoid, is increased 
in monocytes of cirrhotic rats 
23, 24
 and its receptor CB1 is also upregulated in 
the vascular endothelium of patients with cirrhosis
 23
. Infusing monocytes 
isolated from cirrhotic rats into normal rats decreases the mean arterial 
pressure in the recipients. Furthermore, administering a CB1 receptor 
antagonist SR141716A to cirrhotic rats increases the total peripheral 
resistance
23, 24
 both studies demonstrated that SR141716A significantly 
increases the reduced arterial pressure in cirrhosis, and blocks the 
hypotension induced by the infusion of isolated cirrhotic monocytes into 
normal rats 
23, 24
 Batkai and colleagues also found that SR141716A decreases 
mesenteric blood flow and portal venous pressure in cirrhotic rats
23
. All of 
these data indicate that the vascular tone in cirrhosis is regulated by CB1 
receptors in both the splanchnic and systemic circulations. 
Besides vasodilatation, anandamide rapidly and dose-dependently 
induces apoptosis in primary culture-activated and in vivo-activated hepatic 
stellate cells, with over 70% cell death after 4 h at 25 µmol/L
25
. This effect 
could alter the hepatic sinusoidal microcirculation and enhance the 
development of portal hypertension that leads to hyperdynamic circulation. 
How does cirrhosis leads to increased endocannabinoids? Varga and 
co-workers found that bacterial endotoxin stimulates endocannabinoid 
production in cirrhosis
 26
. The upregulation of CB1 receptors in cirrhotic 
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vascular endothelium and thus increased end-organ sensitivity may also 
enhance endocannabinoid vasodilator tone
 23
. 
Nitric oxide 
NO has been extensively studied. It is now clear that in cirrhosis, 
changes in NO activity affect different vascular beds in variable ways. In the 
liver microcirculation, endothelial-constitutive NO synthase (eNOS or 
NOS3) expression is decreased in a cirrhotic rat model
 27
. Simvastatin 
enhances hepatic nitric oxide production and decreases the hepatic vascular 
tone in patients with cirrhosis
28
. An NO donor
29
 or NOS3 gene transfection
27
, 
which compensates for the decreased hepatic NOS3 expression, significantly 
lowers the increased portal pressure in cirrhosis. 
In contrast, systemic NO production is increased in cirrhotic patients 
and animal models
30-32
. Moreover, normalization of NO production in 
cirrhotic rats, by achieving normal concentrations of aortic cGMP with small 
doses of the NOS inhibitor L-NAME, normalizes the decreased peripheral 
vascular resistance and the increased cardiac output
 33
. In vitro, an NO 
inhibitor reverses the hyporeactivity of blood vessels from cirrhotic rats to 
vasoconstrictors
 34
   
All these results strongly support the hypothesis that increased NO 
production is a major factor in the peripheral arterial vasodilation of 
cirrhosis. Agents promoting nitric oxide production include inflammatory 
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cytokines and endotoxin. In that regard, selective intestinal decontamination 
with norfloxacin partially reverses the hyperdynamic circulatory state in 
cirrhotic patients, suggesting a role for the endotoxin-NO pathway
 35
. Where 
does this endotoxin come from in cirrhosis? First, alcohol is a major cause of 
cirrhosis in Western countries, and alcoholic gastrointestinal mucosal 
damage
 36
, could potentially facilitate transfer of bacteria into the circulation. 
Second, portosystemic shunting allows gut-derived bacterial endotoxins 
passage to the systemic circulation. Third, cirrhotic patients with portal 
hypertension show intestinal structural abnormalities characterized by 
vascular congestion and edema, which leads to increased intestinal 
permeability to bacterial toxins
 37
. Fourth, intestinal bacterial overgrowth and 
bacterial translocation are increased in cirrhosis
 38
. Besides endotoxins, the 
other possible factors stimulating NO production include cytokines such as 
TNF-α, IL-1, IL-6, and IFN-γ39-41. Among these, TNF-α has been studied the 
most. Lopez-Talavera et al found that anti-TNF-α antibody increases mean 
arterial pressure and systemic vascular resistance, and decreases cardiac 
index and portal pressure
 42
. In 4-week BDL rats, in parallel with increased 
serum TNF-α, aortic NOS3 expression and serum nitrate/nitrite 
concentrations were increased
 43
. 
Although the evidence is strong that the increased NOS activity in 
cirrhosis plays an important role in hyperdynamic circulation in cirrhosis, it 
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remains obscure which NOS isoform is involved. The majority of previous 
studies have used a nonspecific NOS inhibitor to diminish NO production. 
However, a recent study used aminoguanidine, a preferential inhibitor of 
NOS2 (inducible NOS), and showed that in vivo, the hyperdynamic 
circulation in portal hypertensive rats is reversed
 44
. But in another study 
aminoguanidine had no in vitro effect on the hyporeactivity of aortic rings 
from cirrhotic rats
 45
. We have recently evaluated the activity of the L- 
arginine-NO pathway at different levels
 43
. Although NOS2 mRNA was 
detectable in the cirrhotic aorta, no NOS2 protein was observed in our 
Western blots. It is unclear why the mRNA was not expressed as a protein. It 
might have been degraded or not been transcribed. It is also possible that our 
method of Western blotting did not allow the detection of small amounts of 
NOS2 protein.  
A consistent augmentation in the expression of NOS3 mRNA and 
protein levels is observed in cirrhotic rats. Because NOS3 can be upregulated 
by stimuli such as shear stress and mechanical deformation, some have 
suggested that hyperdynamic circulation is the cause rather than the 
consequence of the activation of the NO pathway 
31, 46, 47
. In addition, there 
may be other reasons for the increased NOS3. Cirrhosis is associated with 
increased levels of estrogens 
48, 49
, and these compounds have been shown to 
upregulate NOS3 activity
50
. Other factors which may stimulate NOS3 
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expression need further investigation. 
What is the role of another isoform of NOS, neuronal NOS (nNOS or 
NOS1)? Xu and his colleagues have demonstrated that nNOS expression is 
significantly increased in rat cirrhotic aortae
 51
. Furthermore, a nNOS-
specific inhibitor, 7-nitroindazole (7-NI), significantly decreased the sodium 
and water retention and normalized the hyperdynamic indices such as 
cardiac index, mean arterial pressure, and systemic vascular resistance in 
these rats
 51
. Biecker et al also showed that nNOS partially compensates for 
the absence of eNOS in producing hyperdynamic circulation in eNOS-gene 
knockout mice
 52
. These data indicate that the nNOS isoform plays a major 
pathogenic role in hyperdynamic circulation, and perhaps even in renal salt 
and water retention in cirrhosis. 
It seems that endocannabinoids and nitric oxide may both play an 
important role in hyperdynamic circulation, but what is the relationship 
between them? The literature remains inconclusive. In a kidney study, 
Deutsch et al found that the vasodilatation of anandamide is NO dependent, 
because the NOS inhibitor L-NAME completely blocked the vasodilatory 
effect of anandamide, similar to a CB1 antagonist
 53
. However, another study 
showed no effect of L-NAME infusion on the hypotensive effects of 
anandamide
 24
. 
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Some studies suggest the possible involvement of other humoral 
vasodilators, but a definitive pathogenic role for any of these substances 
remains elusive. This list includes: glucagons
 54
, prostaglandins
 55
, GABA
56
, 
VIP
 57
, bile acids
 58
, endotoxin, histamine
 59
 and adenosine
60
. 
Central neural mechanisms 
Although most research has focused on the humoral mediators, in 
recent years we and others have shown an important mechanistic role of 
central nervous system (CNS) activation. A decade ago, it was demonstrated 
that primary afferent denervation by capsaicin reversed the hyperdynamic 
circulation in rats with cirrhosis or portal hypertension due to portal vein 
stenosis (PVS)
61
. What is the relationship between the CNS and 
hyperdynamic circulation in portal hypertension? Using c-fos, an immediate-
early gene (whose protein product can be detected by immunohistochemistry 
as Fos), as a marker of central neuronal activation,  it was showed that the 
brainstem and hypothalamic cardiovascular-regulatory nuclei are activated at 
the first day after PVS, whereas the hyperdynamic circulation does not start 
up until 3-5 days after PVS. This time sequence suggests that central neural 
activation is the initiating signal in the pathogenesis of hyperdynamic 
circulation. 
Subsequently, in portal hypertensive rats, when c-fos antisense 
oligonucleotide was microinjected into one of the major cardiovascular-
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regulatory brainstem nuclei, the nucleus tractus solitarius (NTS), to block 
local Fos expression. This treatment completely blocked the development of 
the hyperdynamic circulation, i.e., abnormalities in cardiac output, mean 
arterial pressure and systemic vascular resistance were completely 
eliminated
 62
. In normal control rats, c-fos antisense oligonucleotides had no 
effect
62
. These results indicate that central neural activation is a sine qua non 
for the development of the hyperdynamic circulation in portal hypertension. 
The CNS, as the controller of the circulation, presumably would not 
arbitrarily activate the cardiovascular system without reason. This raises the 
question of what the initiating signal is. Likely, it is somehow related to the 
portal hypertension per se. Moreover, the exact route of signaling from the 
periphery to the CNS remains unclear. The aforementioned capsaicin study 
suggests that primary afferent nerves may be the signaling pathway from the 
periphery to the CNS
 61
. A subsequent study showed that capsaicin-treated 
BDL rats improve the renal function and do not develop ascites
63
. Moreover, 
both BDL-cirrhotic and portal hypertensive rats show diminished Fos 
expression in NTS after capsaicin-induced denervation of the afferent nerves 
as neonates
63
. These observations indicate that intact primary afferent 
innervation is necessary for the central neuronal activation and development 
or maintenance of hyperdynamic circulation. Additionally, sodium retention 
and ascites formation is also dependent on either the presence of 
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hyperdynamic circulation or intact afferent innervation, or both. The 
complex relationship between CNS activation, local or neurohormonal 
humoral factor stimulation, and cardiovascular disturbances in 
cirrhosis/portal hypertension continues to be studied in several labs. 
Cirrhotic Cardiomyopathy   
This syndrome was first described in the late 1960s, although for 
many years, it was mistakenly attributed to latent or subclinical alcoholic 
cardiomyopathy 
64-66
. However, studies in human and animal models with 
nonalcoholic cirrhosis, dating from the mid-1980s showed a similar pattern 
of increased baseline cardiac output with blunted response to stress
 21
. The 
clinical features of cirrhotic cardiomyopathy include blunted systolic and 
diastolic contractile responses to stress, in conjunction with evidence of 
ventricular hypertrophy or chamber dilatation and electrophysiological 
abnormalities including prolonged QT interval. Recent studies suggest the 
presence of cirrhotic cardiomyopathy may contribute to the pathogenesis of 
hepatorenal syndrome precipitated by spontaneous bacterial peritonitis
67 
acute heart failure after insertion of transjugular intrahepatic
 
portosystemic 
shunts (TIPS) 
68, 69
, and increased cardiovascular morbidity and 
 
mortality 
after liver transplantation
70
. Therefore this syndrome is more than
 
an 
academic curiosity, but rather an important clinical entity.  
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Endocannabinoids
 
Endocannabinoids are known to have a negative inotropic effect on
 
cardiac contractility in both human
71
 and rats
72
. The plasma level of an
 
endogenous cannabinoid, anandamide, is known to be increased in    
cirrhosis
 23
. We recently demonstrated a major role for increased local 
cardiac production of endocannabinoids in cirrhotic cardiomyopathy
 73
. This 
conclusion is based on the restoration of blunted contractile response of
 
isolated left ventricular papillary muscles from BDL-cirrhotic rats after
 
preincubation with a CB1 antagonist, AM251. Additionally,
 
endocannabinoid reuptake blockers (VDM11 and AM404) enhance the 
relaxant response of cirrhotic papillary muscle to higher frequencies of
 
contraction in an AM251-sensitive fashion, suggesting an increase in the
 
local production of endocannabinoids acting through CB1 receptors. Other
 
in 
vitro evidence suggests a main neuronal source for the increase in local
 
production of endocannabinoids, as these effects were mostly abolished by 
pretreatment with the neurotoxin tetrodotoxin.
 
β -adrenergic signaling
 
Cardiac-adrenergic signaling is one of the main regulators of cardiac
 
contractility. Adrenergic receptors increase adenylyl cyclase activity through
 
stimulatory G proteins. Increased production of cAMP in turn results in an
 
increase in calcium influx and contractile force mainly through activation of
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protein kinase A (PKA). We have previously shown that expression and
 
responsiveness of β-adrenergic receptors
74
 as well as its post receptor
 
signaling pathway is blunted in cardiac tissue of cirrhotic rats. Post receptor
 
impairment was found at different levels including content and function of
 
stimulatory Gs-proteins
 75
, uncoupling of the β-adrenoceptor-ligand complex 
from G protein
 76
, and responsiveness of adenylyl cyclase to stimuli 
75, 77
. 
Membrane fluidity 
Biochemical and biophysical properties of the cell membrane 
determines the mobility of membrane-bound protein moieties. This mobility 
is known as membrane fluidity
 78
, which is shown to be an important factor 
in the function of a number of membrane-bound receptors including β-
adrenergic receptors
79
. It was shown that membrane fluidity in 
cardiomyocytes from bile duct-ligated rats is decreased in association with 
an increase in membrane cholesterol content and cholesterol/phospholipids 
ratio
 75
. Restoration of these abnormalities in vitro results in normalization of 
blunted response of β-adrenergic receptors
75
. Alterations in membrane 
fluidity may also play a role in abnormal function of other membrane-bound 
components in cirrhotic cardiomyocytes including ion channels. The 
significant decrease in K
+
 currents through Ca
2+
-independent transient 
outward K
+
 channel and the delayed rectifier current reported by Ward et al 
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is an example that requires further investigation
80
. 
Nitric oxide 
Nitric oxide is known to negatively regulate cardiac contractile 
function. It has been shown to be involved in some types of cardiac 
dysfunction including ischemic heart disease
 81
. Balligand et al have reported 
that non-selective blockade of NOS augments the contractile response of rat 
ventricular myocytes to the β-agonist isoproterenol without affecting the 
baseline contractility
 82
. Whether this effect is mediated by the inhibition of 
adenylyl cyclase activity by NO
 83
 or through the second messenger, cyclic 
guanosine monophosphate (cGMP), remains to be elucidated. Possible 
effects of NO on cardiac function in physiological and some 
pathophysiological states were extensively reviewed previously 
84, 85
. 
As noted previously, cirrhosis is known to be associated with NO 
overproduction
 46
. Involvement of NO overproduction in the development of 
cirrhotic cardiomyopathy was first reported in 1996 by Van Obbergh et al in 
the BDL rat. They showed that a nonselective NOS inhibitor, L-NMMA, 
restored the blunted contractile function of isolated heart from cirrhotic rats 
while it had no significant effect in control animals
 86
. A similar effect was 
reported in isolated left ventricular papillary muscles of cirrhotic rats. 
Furthermore, it was observed that iNOS and not eNOS mRNA and protein 
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expression were significantly increased in the heart of a cirrhotic rat
 39
. 
Increased levels of cGMP in cirrhotic ventricles and elevated serum and 
cardiac levels of cytokines like TNF-α suggest a cytokine/iNOS/cGMP 
pathway for this effect
 39
. 
Carbon monoxide 
Carbon monoxide (CO) is mainly produced in the body through the 
action of heme oxygenases. These enzymes are responsible for converting 
heme to biliverdin and CO. Like NO, CO activates soluble guanylate cyclase 
resulting in increased levels of cGMP 
87, 88
. Expression of inducible heme 
oxygenase (HO-1) mRNA was increased in the right ventricle in a canine 
model of congestive heart failure
 89
. We previously reported an increase in 
mRNA and protein expression of HO-1 in left ventricle of bile duct-ligated 
rats, which was associated with an increase in left ventricular cGMP      
levels
 90
. Furthermore, treatment of cirrhotic heart with an HO inhibitor, zinc 
protoporphyrin IX, restored the elevated cGMP levels
 90
. These findings 
suggest the involvement of an HO-CO-cGMP pathway in the development 
of cirrhotic cardiomyopathy. 
Cardiomyopathies 
The cardiomyopathies are a group of diseases that primarily affect the 
heart muscle and are not the result of congenital, acquired valvular, 
hypertensive, coronary arterial or pericardial abnormalities. Two 
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fundamental forms of cardiomyopathy are recognized: (1) a primary type, 
consisting of heart muscle disease predominantly involving the myocardium 
and/or of unknown cause; and (2) a secondary type, consisting of myocardial 
disease of known cause or associated with a systemic disease such as 
amyloidosis or chronic alcohol use. In many cases it is not possible to arrive 
at a specific etiologic diagnosis, and thus it is often more desirable to classify 
the cardiomyopathies into one of three morphologic types (dilated, 
restrictive, and hypertrophic) on the basis of differences in their 
pathophysiology and clinical presentation. About one in three cases of 
congestive heart failure is due to dilated cardiomyopathy (DCM). LV and/or 
right ventricular (RV) systolic pump function is impaired, leading to 
progressive cardiac dilatation. The electrocardiogram (ECG) often shows 
sinus tachycardia or atrial fibrillation, ventricular arrhythmias, left atrial 
abnormality, low voltage, diffuse nonspecific ST-T-wave abnormalities, and 
sometimes intraventricular and/or AV conduction defects. Echocardiography 
shows LV dilatation, with normal, minimally thickened, or thinned walls, 
and systolic dysfunction. Circulating levels of brain natriuretic peptide are 
usually elevated. Hypertrophic cardiomyopathy (HCM) is characterized by 
LV hypertrophy, typically of a nondilated chamber, without obvious cause, 
such as hypertension or aortic stenosis. The ubiquitous pathophysiologic 
abnormality is diastolic dysfunction, which can be detected by Doppler 
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tissue imaging and results in elevated LV end-diastolic pressures; the latter 
may be present despite a hyperdynamic, nondilated LV. The ECG commonly 
shows LV hypertrophy and widespread deep, broad Q waves. 
The hallmark of the restrictive cardiomyopathies (RCMs) is abnormal 
diastolic function .The ventricular walls are excessively rigid and impede 
ventricular filling. In late stages systolic function is also impaired. 
Myocardial fibrosis, hypertrophy, or infiltration due to a variety of causes is 
responsible. ECG often shows low-voltage, nonspecific ST-T-wave 
abnormalities and various arrhythmias. Echocardiography, reveal 
symmetrically thickened LV walls and normal or slightly reduced ventricular 
volumes and systolic function; the atria are usually dilated. 
Doppler echocardiography typically shows diastolic dysfunction. 
Cardiac catheterization shows a reduced cardiac output, elevation of the RV 
and LV end-diastolic pressures, and a dip-and-plateau configuration of the 
diastolic portion of the ventricular pressure pulses resembling constrictive 
pericarditis. 
Cirrhotic cardiomyopathy 
In the absence of specific diagnostic criteria, the exact prevalence of   
cirrhotic cardiomyopathy remains unclear. At present, cirrhotic 
cardiomyopathy can be defined as the constellation of one or more of these 
following factors
74
: 
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 Normal or increased left ventricular systolic contractility at rest, but 
attenuated systolic or diastolic responses to stress stimuli,   
 Structural or histological changes in cardiac chambers, 
Electrophysiological abnormalities such as prolonged 
ectrocardiographic QT interval,   
 Serum markers suggestive of cardiac stress. 
Systolic dysfunction  
Despite the increased or normal cardiac output at rest, under 
physiological stress cirrhotic patients fail to mount an adequate stimulatory 
cardiac response. Gould et al documented in cirrhotic patients that with 
exercise the left ventricular end-diastolic and pulmonary arterial pressures 
increased with no change in the cardiac index. In other words, cardiac output 
did not increase despite increased ventricular filling pressures, which 
indicates a highly impaired ventricular response
91
. Similarly Grose et al 
showed that when cirrhotic patients underwent maximal exercise, cardiac 
output increased by only 97%; this is considered inadequate when compared 
to approximately 300% increase in healthy controls
92
. Similar blunted 
cardiac systolic response to exercise was also demonstrated by Wong et al
93
; 
moreover patients with ascites showed greater dysfunction than those with 
preascitic cirrhosis.   
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The cardiac response to different physiological stimuli, including 
Valsalva‟s maneuver, ice-cold skin stimulation, and mental stress was 
investigated by Lunzer et al and found to be inadequate
94
. Lee and 
colleagues showed an inappropriate decrease in the cardiac output in the 
postprandial state in cirrhotic patients
95
. Blunted cardiac responsiveness has 
been reported in response to other pharmacological agents. Limas et al 
showed that angiotensin infusion in cirrhotics resulted in an increase in the 
pulmonary wedge pressure, which reflects left ventricular filling pressure, 
without any change in the cardiac output
96
. Blunted cardiac 
responsivenesshas also been documented in response to catecholamine 
infusions
97
. 
Diastolic dysfunction  
Diastolic dysfunction is thought to be more prevalent in cirrhotic 
patients
98
. This is manifested by a stiff, noncompliant ventricle that impairs 
diastolic filling. Finucci et al compared the diastolic function in 42 cirrhotic 
patients with 16 healthy controls. The cirrhotic patients had increased left 
ventricular end-diastolic and left atrial volumes, stroke volume, and late 
diastolic flow velocity compared to normal controls; these results indicate an 
impaired left ventricular relaxation in the cirrhotic patients
98
. A widely-used 
index of diastolic function is the echocardiographic E/A ratio. This is the 
velocity of the diastolic early filling wave (E) divided by the velocity of the 
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late (or atrial) filling wave (A). Normally, this ratio is >1. Many studies have 
demonstrated a low E/A in patients with cirrhosis
99
. 
Structural/histological changes  
Multiple studies were conducted to evaluate the heart mass in patients 
with liver cirrhosis. Most studies did not show any significant structural 
changes in liver cirrhotic patients
100
. However, some have reported changes 
of left ventricular hypertrophy in both humans and in portal hypertensive 
rats
84
. Studies evaluating the heart mass using echocardiography reported 
enlarged left atrial volumes with normal ventricular volumes
101
. Others 
however, reported increases in both the end-diastolic and end-systolic 
volumes of the left ventricle
102
. Changes involving the right heart chambers 
are less pronounced and were normal in most studies
103
. These cardiac 
changes may be related to the hyperdynamic circulation of cirrhosis and 
were correlated with its severity in some studies. The presence of cardiac 
histological changes has been described in several autopsy studies. Findings 
include myocardial hypertrophy, cardiomyocyte edema, fibrosis, nuclear 
vacuolation, and unusual pigmentation
103
. However, these changes were 
reported from studies dating back at least 50 years in patients suffering from 
alcoholic cirrhosis. Lunseth et al studied the autopsies of 108 patients with 
cirrhosis from all causes (although most were alcoholic) and demonstrated 
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the same cellular myocardial abnormalities that were described in earlier 
studies
104
. Other studies conducted on animal models including some of our 
work on long-term bile duct ligated cirrhotic rats failed to show any 
histological changes by light microscopy
105
. This discrepancy between the 
histological changes in human and animal studies is probably related to the 
long disease duration in cirrhotic patients versus the much shorter periods 
needed to induce cirrhosis in animal models. 
Electrophysiological abnormalities  
QT prolongation has been described in patients with liver disease and 
is significantly related to the severity of the underlying liver disease
106
. 
However, significant ventricular arrhythmias and sudden cardiac death 
remain uncommon. The prolonged QT interval is thought to revert to normal 
following improvement in liver function and liver transplantation
107
. The 
effect of β-adrenergic blockade on the prolonged QT interval in cirrhotic 
patients was also evaluated and was found to reduce the prolonged QT 
interval towards normal
108
. Henriksen et al examined the temporal relation 
between electrical and mechanical systole in patients with liver cirrhosis and 
in addition to the prolonged QT interval in their study population they also 
showed alteration in the cardiac excitation-contraction temporal 
relationship
109
. In conclusion the prolonged QT interval is well linked to 
liver disease and is a feature of cirrhotic cardiomyopathy. Its exact 
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mechanism and its prognostic significance require further study. 
Serum markers  
Cardiac troponin I and the family of natriuretic peptides were noted to 
be elevated in cirrhotic cardiomyopathy, possibly reflecting the underlying 
myocardial strain. Atrial natriuretic peptides (ANP) are released mainly by 
the atria in response to stretch, and brain or B-type natriuretic peptide (BNP) 
by the ventricles
110
. Troponin I increases in conditions leading to ventricular 
hypertrophy or dilatation. Pateron et al showed an increased serum troponin I 
level in about 1/3 of cirrhotic patients. Elevated levels correlated with 
decreased ventricular stroke volume index
111
. In cirrhotic patients, BNP 
levels correlated significantly with septal thickness and end-diastolic left 
ventricular diameter 
112,113
.  These results suggest the potential role of these 
markers for screening patients with cirrhosis for the presence of cirrhotic 
cardiomyopathy, and thereby identifying such patients for further 
investigations. 
Echocardiography 
Echocardiography increasingly has become a key component in the 
routine evaluation of patients with suspected or known cardiovascular 
disease. Two-dimensional (2D) echocardiography is able to visualize the 
heart directly in real time using ultrasound, providing instantaneous 
assessment of the myocardium, cardiac chambers, valves, pericardium, and 
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great vessels. Doppler echocardiography measures the velocity of moving 
red blood cells and has become a noninvasive alternative to cardiac 
catheterization for assessment of hemodynamics. 
2D echocardiography is an ideal imaging modality for assessing left 
ventricular (LV) size and function. 2D echocardiography is useful in the 
diagnosis of LV hypertrophy and is the imaging modality of choice for the 
diagnosis of hypertrophic cardiomyopathy. Other chamber sizes are assessed 
by visual analysis, including the left atrium and right-sided chambers. 
Doppler echocardiography uses ultrasound reflecting off moving red blood 
cells to measure the velocity of blood flow across valves, within cardiac 
chambers, and through the great vessels. Normal and abnormal blood flow 
patterns can be assessed noninvasively. Color-flow Doppler imaging 
displays the blood velocities in real time superimposed upon a 2D 
echocardiographic image. Doppler echocardiography allows noninvasive 
evaluation of ventricular diastolic filling. The transmitral velocity curves 
reflect the relative pressure gradients between the left atrium and ventricle 
throughout diastole. They are influenced by the rate of ventricular relaxation, 
the driving force across the valve, and the compliance of the ventricle. There 
is a progression of diastolic dysfunction, which can be assessed by Doppler 
flow velocity curves. In the early phase of diastolic dysfunction there is 
primarily an impairment of LV relaxation, with reduced early transmitral 
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flow and a compensatory increase in flow during atrial contraction. As 
disease progresses, and ventricular compliance declines, left atrial pressure 
rises, resulting in a higher early transmitral velocity and shortening of the 
deceleration of flow in early diastole so that the filling pattern becomes 
normal, termed pseudonormalization. In patients with the most severe 
diastolic dysfunction and further elevation of left atrial pressure, early 
diastolic flow velocity rises further, termed the restrictive filling  pattern. 
The addition of analysis of Doppler tissue velocities of annular motion 
provides further information concerning the diastolic properties. The systolic 
function is evaluated with the following parameters in echocardiography. 
Ejection fraction   
Simpson‟s apical biplane method is recommended as the accurate 
echo measure of LVEF. 
 Fractinal shortening at endocardium and midwall   
 Stress-shortening relations   
 Pressure volume analysis   
The prevalence and extent of systolic dysfunction in cirrhotic patients 
variable.  If present, it is unlikely to manifest itself without a stimulus. 
Stroke volume and contractile indices such as dP/dt (ﬁrst derivative of 
ventricular pressure generation) typically are normal or even increased at 
rest.  Conventional Doppler echocardiography is the method of choice in 
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assessment of diastolic function. The peak velocities of LV filling during the 
early rapid (E wave), atrial contraction (A wave) phases, the ratio of the 2 
filling velocities (E/A ratio), E wave deceleration time and the isovolumetric 
relaxation time are recorded at end-expiration for 5 consecutive beats at 
baseline and again during the phase of Valsalva maneuver.  Diastolic 
dysfunction represents a decrease in left ventricular filling and reduced 
possibility to maintain stroke volume without a compensatory increase of 
atrial filling pressures. This condition usually precedes the development of 
systolic dysfunction and is the main determinant of heart failure. Diastolic 
dysfunction appears to be more prevalent in patients with cirrhotic 
cardiomyopathy. 
Electrocardiogram 
The electrocardiogram is a graphic recording of electric potentials 
generated by the heart. The signals are detected by means of metal electrodes 
attached to the extremities and chest wall and are then amplified and 
recorded by the electrocardiograph. ECG leads actually display the 
instantaneous differences in potential between these electrodes. 
Electrophysiological changes including prolonged depolarization and 
impaired cardiac excitation-contraction coupling been demonstrated in 
cirrhotic patients. Repolarization prolongation manifested by a prolonged 
QT interval (more than 440 msec) on the electrocardiogram is found in 30–
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50% of patients with cirrhosis.  Severity of liver disease seems to be 
correlated to the degree of QT prolongation. These changes disappear after 
liver transplantation in most patients. 
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MATERIALS AND METHODS 
 
The present study was conducted in the Kilpauk Medical College 
Hospital, between November 2009 and October 2010. 100 patients of 
chronic liver disease were selected for the study. These patients were 
admitted in the general medical wards. 
Criteria followed for selection of patients includes: 
1. Only patients with clinical, biochemical and sonographic evidence of 
chonic liver disease – cirrhosis were selected. 
2. Patients with previously detected heart disease were excluded from the 
study. 
3. Patients  with  inter current  illness and  those  who  were critically ill 
were  excluded  from  the  study. 
4. Patients with cardiac cirrhosis were excluded from the study. 
A  detailed  history  was  elicited  from   the   patient  with  special 
reference  to  cardiovascular  symptoms. A thorough  physical  examination 
was  performed  in  the patients  and  a  special note  was  made regarding  
heart rate & rhythm,  blood  pressure, jugular  venous  pulse  and  pressure  
and  precordial  examination. 
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All patients were subjected to routine investigations viz, Blood urea 
sugar, complete haemogram, serum cholestrol & liver function tests. All 
patients were subjected to ultrasound scan abdomen to confirm the diagnosis 
of chronic liver disease. Patients with ascites underwent abdominal 
paracentesis and fluid was analyzed for protein content and cells. All patients 
were then subjected to electrocardiography, chest X-ray and M- mode 2-
Dimensional echocardiography.  
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RESULTS AND OBSERVATION 
Fig 9 
 
 
 
 
 
 
 
 
Out of the 100 patients studied 70 (70%) were males and 30 (30%) 
were females (Fig 9). The age of the patients ranged from 19 years to 75 
years. 
Fig 10 
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10 Patients (10%)  were   alcoholics,   28 patients (28%)  had  past 
history  of  jaundice or, 16 patients (16%)  presented  with  haemetemesis         
(fig : 11 ) on  admission  and  54 patients (54%)  had  ascites, 18 patients 
(18%) had  jaundice  and  12 patients (12%)  had  clinically  detectable 
splenomegaly  on  admission. Among this 8 patients were HbsAG+ (8%) and 
4 patients were diabetics (4% (fig : 10). All patients had sonographic 
evidence of cirrhosis with portal hypertension. 
 
TYPE OF CLINICAL RESENTATION   
Fig 11 
   
 
 
 
 
 
 
 
 
 
Regarding  the  cardiovascular  examination  40 (40 %) out of 100  
Patients  had  symptoms  referable  to the heart  table  below : 
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CARDIO VASCULAR SYMPTOMS AND SIGNS 
S. No VARIABLE MEAN RANGE 
1 SYMPTOMS PRESENT  40 - 
2 PULSE RATE 84/min 54 TO 120/MIN 
3 JVP ELEVATION  12% - 
4 BLOOD PRESSURE  
SYSTOLIC 
DIASTOLIC  
MAP 
 
110 mmHg 
70 mmHg 
84 mmHg 
 
90 to 160 mmHG 
50 to 100 mmHG 
70 to 110 mmHG 
5 HEART MURMURS 6 % - 
6 CONGESTIVE 
CARDIAC FAILURE 
6 % - 
 
6 Patients (6%) had congestive cardiac failure. The average pulserate 
was 84 and it ranged from 54/m to 120/m. The jugular venous pressure was 
elevated in 12 (12%) patients. The systolic blood pressure ranged from 
90mmHg to 160 mm Hg, the average being 110.mmHg. The diastolic blood 
pressure ranged from 50mmhg to 100 mm Hg, the average being 70 mmHg. 
The mean arterial pressure ranged  from 70 mmHg  to 110mmHg  the 
average  being 86 mmHg Functional  high output systolic  flow murmur  was  
detected in 6 (6%)  patients.   
  
66 
 
Out of 100 patients 6 patients had elevated blood pressure. Previous 
studies shows  that  the  systolic  blood pressure  more  than  160mm HG and  
diastolic  blood pressure  more  than 95 mmHg  are  the  range  for  
hypertension  in  cirrhorotic  patients.   
 
X- RAY CHEST IN ASCITES PATIENT 
Fig 12 
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The electro cardiac gram showed an average heart rate of 82 / m. The 
low QRS voltage in chest leads and limb leads were found in 20 patients. T 
wave inversion was found in chest leads (V1 to V3/ V6) in 8 (8%) patients, in 
II, III avf in 14 patiens (14%). Regarding  Hemiblock 4 (4%) cases  were 
observed  in  the study. qs complex  in  anterior & Inferior leads  is  seen  in  
8 patients (8%). 
  The chest roentgenogram showed Hepatic Hydrothorax in 10 patients 
(10%).  Cardio megaly was evident in chest X – ray in 22 patients (22%) 
(Fig: 12).  
M-Mode 2 Dimensional Echocardiographic studies, done showed 
abnormality in 30 (30%) patients.  Pericardial effusion (fig: 13) was detected 
in 8 (8%) patients. Regarding enlargement of cardiac chambers – all 4 
chambers were enlarged in 6 (6%) patients. With global hypokinesia and left 
ventricular hypertrophy in 2 (2%) patient. Two cases of porto Pulmonary HT 
was observed in our study (2 %). Akinesia of inferior and anterior wall was 
seen in 8 (8%) patients and hyperdynamic flow due to anemia  was  observed  
in 4  patients (4 %). 
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FIG.13.ECHO SHOWS MILD PERICARDIAL EFFUSION 
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DISCUSSION 
The  aetiology  of  cirrhosis (chronic  liver  disease) in  patient  
under  study  showed a slightly higher incidence of  post hepatic or post 
necrotic cirrhosis  as  compared to western studies.   
With regard to the cardiovascular evaluation, the average heart rate 
in present study was 84±2 beats per minute. Other studies showed the 
average heart rate as follows.  
Lenz K, Lleinberger G et al 1985  –  101/min +2 Vs 78 
Bernard M, Rubbloli et al 1991  -  79/min +2 Vs 71 
McCormnick P.A; Chin J et al 1995 - 101/min + 2 Vs 78 
Present study 2006    -  84±/ min Vs 74 
 Thus the present study confirms that there is an increase in heart rate 
is cirrhosis liver as compared to the average heart rate of healthy subjects, 
reflecting a hyper dynamic circulatory state.  
 The average systolic blood pressure, diastolic blood pressure and 
mean arterial pressure in the present study were 110/ Hg and 70mm/Hg and 
86mmHg respectively. In the other studies they were as follows.  
 Lenz L; Kleinberger G et al 1995 - Diastolic pressure 56 Vs 
McCormick PA, Chin H et al 1995 -86- Mean arterial pressure.  
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The present study shows that the mean arterial pressure is comparable 
with that of the study done by McCormick P.A et al but the diastolic 
pressure is within the normal range.  
The elevation of jugular venous pulse in 12% of patients reflects an 
increase in the plasma volume and fluid over load. Significant correlation 
was demonstrated between the heart rate and mean arterial pressure both of 
which indicate a hyper dynamic circulation and serum albumin and serum 
bilirubin levels both of which are indicators of liver dysfunction. The present 
study clearly demonstrated that hyperdynamic circulation progressively 
increase with the severity of the liver dysfunction. The study quoted for this 
include Meng HG, Lin HC et al 1994 which  also concludes that the severity 
of cirrhosis is  closely related to the degree of hyperkinetic circulatory state 
and portal hypertension. Signification positive correlation was noted 
between decreased MAP in 36% and increased HR in 54% similarly 
decreased serum albumin in 32% and increased serum bilirubin in 44%. 
The present study shown that out of 100 patients 6 patients are 
hypertensive 6%. 
Regarding the electrocardiographic findings not many studies are 
available showing the various electrocardiographic abnormalities in cirrhosis 
liver. It has been said that cardiac arrhythmias in cirrhosis liver are always 
due to a definable precipitating event such as hypo or hyper kalemia, 
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acidosis, hypoxia or cardiac irritation due to insertion of lines, although in 
older patients the possibility of ischemic heart disease must not be ignored. 
One study by Walt, Toyonaga A et al 1995 demonstrated that cardiac 
arthythmias in common during surgery, the commonest arrhythmias is 
common during surgery, the commonest arrhythmias being premature 
ventricular contraction. The current study shows that low voltage QRS 
complexes were present in 20 patients. Out of which 8 had pericardial 
effusion probably reflecting the presence of occult pericardial effusion. T 
were inversion was noted in the precordial leads & limb leads in 22 patients 
and CAHD changes in 8 patients had no symptoms referable to the cardiac 
system.  
S.NO ECG ABNORMALITIES 
INCIDENCE 
N=48 
% 48 
1 Low voltage complexes  20 20 
2 CAHD          old infarction                               
                    ischemic changes  
8
20 
8 
20 
 
Chest roentgenograms showed that the elevated hemidiaphragms were the 
commonest abnormality detected and all these patients had ascites and the 
elevated hemidiaphragms probably reflecting increased intra-abdominal 
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pressure. Cardiomegaly was detected in 22 patients. Hepatic Hydrothorax 
was found in 10 patients. 
Chest roentgenograms evaluation of patients under study is an follows 
x-Ray changes Incidence N=32 % 32 
Cardiomegaly  22 22 
Hepatic hydrothorax  10 10 
 
Echocardiographic evaluation of patients under study is as follows 
S. No Echo Abnormalities Incidence N=30 %30 
1 Cardiomyopathy Global 
Hypokinesia & Chamber 
enlargement Present.  
6 (Out of 6, Two 
patients are 
alcoholic ) 
6 
2 Pericardial Effusion  8 8 
3 CAHD changes  10 10 
4 Porto Pulmonary HT 2 2 
5 Hyper dynamic flow due to 
anemia  
4 4 
6 LV Dysfunction (LUEF 
<49%)  
6 6 
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Moderate Anemia <10 g % severe Anemia < 7 to 8 gm % (fig 14) 
Current study shows that all the 100 patients were anemic that is           
<10gm %. Among this 48 (48%) patients were severely anemic and 52 
(52%) patients are moderately anemic.  
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CONCLUSION 
1. The  result of  this  study clearly show  that large  number of  patients, 
Chronic liver Disease with hepatic cirrhosis are asymptomatic (40%) 
with regard to cardiovascular system, have evidence of cardiac 
involvement in electrocardiography and echo cardiography  
2. Cardiac decompensation in cirrhosis is rare despite the high output state 
and its presence as indicated by left ventricular systolic dysfunction. 
3. The   incidence  of  hypertension  in chronic  liver  disease  ( cirrhosis)         
patients,  our  study  shows  6 patients ( 6 % ). 
4. Electrocardiographic  abnormalities  includes  low  voltage  complexes 
due  to  pericardial  effusion non specific T  wave  abnormalities  and 
CAHD  changes. 
5. Cardiomyopathy,  pericardial  effusion, portopulmanary   hypertension 
and  CAHD  are  the Echocardiographic  abnor -malities  detected  in  
this  study.   
6. All the  patients  were  anemic, either  the  hyperdynamic  circulation 
and  hyperkinetic syndrome  is due   to cirrhosis or due to anemia I still 
in controversy. Further it needs a long term follow up and study.   
7. Cardiac  evaluation  is  a  pre-requisite  in  patients  with  cirrhosis 
undergoing  stress  like  surgery  because  the  presence  of  cardiac 
involvement adds  to  the  morbidity  and  mortality.  
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CARDIOVASCULAR CHANGES IN CHRONIC LIVER 
DISEASE 
PROFORMA 
 
NAME:  AGE    SEX M/F   D.O.A 
OCCUPATION : I.P.NO      D.O.A 
ALCOHOLIC :    NON –ALCOHOLIC 
KNOWN CARDIAC PATIENT  YES / NO 
 
COMPLAINTS 
ABDOMINAL PAIN   ABD MASS   JAVNDICE 
ABD DISTENTION    HAEMATEMESIS  MALENA.  
 
 
CLINICAL FINDINGS 
JAUNDICE   HEPATOMEGALY  SPLENOMEGALY 
PEDAL OEDEMA  JVP ↑ 
PULSE:   BP:     MAP: 
 
INVESTIGATIONS 
 
Hb  :   Blood Sugar : 
Tc :   Blood Urea : 
Dc  :   Serum Creatinine : 
RBC  :   Serum Electrolytes :  Na+ : 
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PLATELETS:       K+: 
PCV :    LET     Ascitic Fluid  
URINE   ALB:  Sr Bilirubin: 
   SUG:  SGOT: 
   DEP:  SGPT: 
     SAP: 
HBsAG:    Sr Protein: 
Sr. Ceruloplasmin :   Albumin: 
      Globulin: 
ECG:    CXR: 
 
USG ABDOMEN:  OGD: 
 
ECHOCARDIOGRAM:  
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ABBREVIATION 
ANP  Atrial  Natriuretic Peptide 
cAMP Cyclic Adenosine Monophosphate 
cGMP Cyclic Guanosine Monophosphate 
CO  Carbon Monoxide  
DCM  Dilated Cardiomyopathy 
E/A  E – Early Filling Wave 
  A – Atrial Filling Wave 
HCM  Hypertrophic Cardiomyopathy 
HO-1  Heme Oxygenase 
HVPG Hepatic Venous Pressure Gradient  
NO  Nitric Oxide 
NOS  Nitric Oxide Synthase 
RCM  Restrictive Cardiomyopathy  
TIPS  Transjugalar Intrahepatic Portosystemic Shunt 
TNFα  Tumour Necrosis Factor α 
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KEY WORDS TO MASTER CHART  
S.No   Serial Number 
HR   Heart Rate 
Sys BP  Systolic Blood Pressure  
Dias BP  Diastolic Blood Pressure 
MAP   Mean Arterial Pressure 
Hb   Haemoglobin 
Sr.Bil   Serum Bilirubin 
Sr.Alb  Serum Albumin 
Bld.Urea  Blood Urea 
USG Abd  Ultra Sonogram Abdomen 
CXR   Chest X-ray 
Echo   Echocardiogram 
Cirrh/PHT  Cirrhosis / Portal Hypertension 
CAHD  Coronary Artery Heart Disease 
LV Dysfunction Left Ventricular Dysfunction 
IWMI  Inferior Wall Myocardial Infarction 
AWMI  Anterior Wall Myocardial Infarction
  
1 
S. No 
Name 
Age / 
Sex 
HR 
Sys 
BP 
Dias 
BP MAP Hb% 
Sr. 
bil 
Sr. 
alb 
BLD 
Urea USG ABD CXR ECG ECHO 
1 Ramalingam 52/M 84 100 70 80 6.2 6.8 3.5 30 Cirrh/PHT Cardiomegaly Ishaemic Changes  CAHD Chages  
2 Agbar 55/M 88 110 70 84 5 1 3.5 15 Cirrh/PHT Normal Normal Normal 
3 Kamala 58/F 92 110 80 90 7.8 0.9 2 39 Cirrh/PHT Cardiomegaly Low voltage complex Hyperdynamic flow 
4 Baby 59/F 76 160 100 120 9.4 1 3.7 30 Cirrh/PHT Cardiomegaly Low voltage complex CAHD Chages  
5 Ravi 28/M 89 120 80 94 10.4 6 3 24 Cirrh/PHT Normal Normal Normal 
6 Arunchalam 45/M 92 110 70 84 8 1.2 3.4 36 Cirrh/PHT Normal Normal Normal 
7 Rathna 55/F 72 120 80 94 9 0.8 3.2 52 Cirrh/PHT Normal Normal Normal 
8 Moorthy 39/M 86 100 70 80 5.8 0.6 2.6 182 Cirrh/PHT Normal Normal Normal 
9 Karuppaiya 49/M 82 110 60 76 9 5.8 3 34 Cirrh/PHT Cardiomegaly Ishaemic Changes  CAHD Chages  
10 Dharmaraj 35/M 74 160 96 113 9.2 1.4 2.8 36 Cirrh/PHT Normal Normal Normal 
11 Muthu 75/M 88 120 80 94 6 1.4 4.1 35 Cirrh/PHT Cardiomegaly Old IWMI LV Dysfunction  
12 Shanmugam 40/M 64 130 80 96 3.4 0.8 3.4 25 Cirrh/PHT Normal Low voltage complex Pulmonary Hypertension  
13 Madhavan 46/M 78 130 80 96 9 2.4 3 34 Cirrh/PHT Normal Low voltage complex Normal 
14 Balaganesh 39/M 98 100 70 80 6 0.1 2.8 37 Cirrh/PHT Normal Normal Normal 
15 Kumar 40/M 88 120 80 94 8.5 1.2 2.5 53 Cirrh/PHT Hydrothorax Ishaemic Changes  Pericardial effusion 
16 Thiyagarajan 19/M 76 110 70 84 9.2 1.6 3 16 Cirrh/PHT Normal Normal Normal 
17 Padma 30/F 76 100 70 80 8 1.4 2.7 16 Cirrh/PHT Normal Normal Normal 
  
2 
18 Babu 50/M 84 120 80 94 8 0.9 3.2 55 Cirrh/PHT Hydrothorax Ishaemic Changes  Pericardial effusion 
19 Kathaiyan 40/M 86 100 70 80 7.8 1.2 3.4 36 Cirrh/PHT Hydrothorax Ishaemic Changes  Pericardial effusion 
20 Arumugam 30/M 90 120 80 94 7.2 4 3 28 Cirrh/PHT Normal Normal Normal 
21 Sivapakkiam 40/F 88 110 70 83 6.8 1.4 3.3 41 Cirrh/PHT Normal Normal Normal 
22 Munusamy 19/M 86 120 70 86 7 1.4 3.4 3.2 Cirrh/PHT Normal Normal Normal 
23 Subramani 48/M 80 180 100 126 10.2 1.8 3.1 34 Cirrh/PHT Normal Low voltage complex Normal 
24 Jaya 47/F 96 120 80 94 9.2 1 2.3 34 Cirrh/PHT Normal Normal Normal 
25 Selvamani 50/M 98 120 70 86 8 3.4 2.7 28 Cirrh/PHT Normal Ishaemic Changes  Hyperdynamic flow 
26 Suguna 48/F 80 110 80 90 6.4 2 3.4 22 Cirrh/PHT Normal Low voltage complex Normal 
27 Noornisha 27/F 88 110 70 84 8.8 0.8 3.2 28 Cirrh/PHT Normal Normal Normal 
28 Anand 60/M 90 100 70 80 4.6 0.8 3.3 22 Cirrh/PHT Hydrothorax Normal Pericardial effusion 
29 Ramesh 74/M 86 140 80 100 8.2 1.4 3 18 Cirrh/PHT Cardiomegaly Old AWMI LV Dysfunction 
30 Porkodi 35/F 82 120 80 94 6.2 1.4 2.8 24 Cirrh/PHT Normal Normal Normal 
31 Yusuf 39/M 96 110 70 84 7.2 8.2 3.4 18 Cirrh/PHT Normal Normal Normal 
32 Mani 63/M 88 120 70 86 2.8 0.9 3.2 32 Cirrh/PHT Normal Ishaemic Changes  Normal 
33 Arumugam 65/M 86 110 80 90 9.2 0.8 3 28 Cirrh/PHT Cardiomegaly Old IWMI LV Dysfunction 
34 Ragumansha 52/M 98 100 80 86 6.4 1.6 2.8 23 Cirrh/PHT Normal Normal Normal 
35 Hema 50/F 80 130 80 96 8.2 1.4 2.7 17 Cirrh/PHT Normal Normal Normal 
  
3 
36 Ratha 40/F 92 110 70 84 8.6 0.8 2.7 21 Cirrh/PHT Normal Normal Normal 
37 Padmavathi 30/F 84 110 70 83 8.8 0.8 3.5 15 Cirrh/PHT Normal Normal Normal 
38 Raman 47/M 80 110 80 90 9.2 1.2 3.2 24 Cirrh/PHT Normal Low voltage complex Normal 
39 Muthu 60/M 84 120 80 94 8.6 0.8 3.5 36 Cirrh/PHT Cardiomegaly Ishaemic Changes  Normal 
40 Raja 45/M 80 110 80 90 5.6 2.6 3 43 Cirrh/PHT Cardiomegaly Ishaemic Changes  Normal 
41 Dakshinamoorthy 65/M 96 120 80 94 9.2 1.2 2.5 46 Cirrh/PHT Normal Old AWMI Normal 
42 Arockia Mary 52/F 85 140 70 84 8 0.8 3.5 33 Cirrh/PHT Normal Normal Normal 
43 Ragavan 51/M 88 110 70 84 9.4 0.6 2.3 40 Cirrh/PHT Normal Low voltage complex Normal 
44 Kannan 50/M 84 110 80 90 4 0.8 2.8 38 Cirrh/PHT Normal Normal Normal 
45 Kaliaperumal 55/M 84 120 80 94 9.2 0.8 3.3 30 Cirrh/PHT Cardiomegaly Low voltage complex Normal 
46 Senthil 42/M 90 110 70 84 8.6 1 4 19 Cirrh/PHT Cardiomegaly Ishaemic Changes  CAHD Chages  
47 Kamatchi 40/F 96 110 80 90 9.8 4 3 21 Cirrh/PHT Normal Normal Normal 
48 Lakshmi 35/F 80 110 70 84 7.6 1.2 2.6 94 Cirrh/PHT Normal Normal Normal 
49 Samikannu 65/M 98 120 80 94 6.4 3 2.4 56 Cirrh/PHT Cardiomegaly Low voltage complex Normal 
50 Dhatayuthapani 53/M 76 130 80 96 8.2 2.8 3.7 42 Cirrh/PHT Normal Normal Normal 
51 Subbiah 42/M 64 130 80 96 3.4 0.8 3.4 25 Cirrh/PHT Normal Low voltage complex Normal 
52 Sreedhar 38/M 98 100 70 80 6 0.1 2.8 37 Cirrh/PHT Normal Normal Normal 
53 Hari Krishnan 74/M 86 140 80 100 8.2 1.4 3 18 Cirrh/PHT Cardiomegaly Old AWMI LV Dysfunction 
  
4 
54 Pandi 74/M 88 120 80 94 6 1.4 4.1 35 Cirrh/PHT Cardiomegaly Old IWMI LV Dysfunction (Diastolic) 
55 Duraisamy 60/M 90 100 70 80 4.6 0.8 3.3 22 Cirrh/PHT Normal Ishaemic Changes  Normal 
56 Adhikesavan 21/M 76 110 70 84 9.2 1.6 3 16 Cirrh/PHT Normal Normal Normal 
57 Sanmugam 52/M 84 100 70 80 6.2 6.8 3.5 30 Cirrh/PHT Normal Low voltage complex Hyperdynamic flow 
58 Natesan 48/M 78 130 80 96 9 2.4 3 34 Cirrh/PHT Hydrothorax Normal Normal 
59 Gowri 32/F 88 110 70 84 8.8 0.8 3.2 28 Cirrh/PHT Normal Normal Normal 
60 Murali 55/M 86 110 70 84 5 1 3.5 15 Cirrh/PHT Normal Ishaemic Changes  Normal 
61 Nelson 48/M 80 180 100 126 10.2 1.8 3.1 34 Cirrh/PHT Normal Ishaemic Changes  Normal 
62 Parasuraman 30/M 82 120 80 94 10.4 6 3 24 Cirrh/PHT Normal Normal Normal 
63 Vinayagam 40/M 86 100 70 80 7.8 1.2 3.4 36 Cirrh/PHT Hydrothorax Normal Pericardial effusion 
64 Arusiya 52/F 72 120 80 94 9 0.8 3.2 52 Cirrh/PHT Normal Normal Normal 
65 Kumarasen 50/M 84 120 80 94 8 0.9 3.2 55 Cirrh/PHT Hydrothorax Normal Pericardial effusion 
66 Ramakrishnan 45/M 92 110 70 84 8 1.2 3.4 36 Cirrh/PHT Normal Low voltage complex Normal 
67 Perumal 53/M 82 110 60 76 9 5.8 3 34 Cirrh/PHT Normal Ishaemic Changes  Normal 
68 Jayasankar 35/M 74 160 96 113 9.2 1.4 2.8 36 Cirrh/PHT Normal Normal Normal 
69 Kajendran 41/M 86 100 70 80 5.8 0.6 2.6 182 Cirrh/PHT Normal Low voltage complex Normal 
70 Manivannan 65/M 84 120 80 94 9.2 1.2 2.5 46 Cirrh/PHT Cardiomegaly Ishaemic Changes  CAHD Chages  
71 Malliga 35/F 82 120 80 94 6.2 1.4 2.8 24 Cirrh/PHT Normal Normal Normal 
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72 Kesavan 60/M 84 120 80 94 9.2 0.8 3.3 30 Cirrh/PHT Hydrothorax Normal Pericardial effusion 
73 Loganathan 64/M 88 120 70 86 2.8 0.9 3.2 32 Cirrh/PHT Cardiomegaly Low voltage complex Normal 
74 Narayani 35/F 80 110 70 84 7.6 1.2 2.6 94 Cirrh/PHT Normal Normal Normal 
75 Manickam 39/M 94 110 70 84 7.2 8.2 3.4 18 Cirrh/PHT Normal Low voltage complex Normal 
76 Jayaraman 65/M 98 120 80 94 6.4 3 2.4 56 Cirrh/PHT Normal Ishaemic Changes  Normal 
77 Malar 31/F 84 110 70 83 8.8 0.8 3.5 15 Cirrh/PHT Normal Normal Normal 
78 Kuppasamy 65/M 86 110 80 90 9.2 0.8 3 28 Cirrh/PHT Cardiomegaly Old AWMI Normal 
79 Kanniyappan 53/M 78 130 80 96 8.2 2.8 3.7 42 Cirrh/PHT Normal Normal Normal 
80 Krishnan 58/M 84 120 80 94 8.6 0.8 3.5 36 Cirrh/PHT Cardiomegaly Ishaemic Changes  CAHD Chages  
81 Anusa 45/F 80 110 80 90 6.4 2 3.4 22 Cirrh/PHT Cardiomegaly Normal CAHD Chages  
82 Murali 40/M 88 120 80 94 8.5 1.2 2.5 53 Cirrh/PHT Normal Normal CAHD Chages  
83 Amudha 61/F 76 160 100 120 9.4 1 3.7 30 Cirrh/PHT Cardiomegaly Normal Normal 
84 Easwari 35/F 90 120 80 94 7.2 4 3 28 Cirrh/PHT Normal Normal Normal 
85 Balammal 30/F 74 100 70 80 8 1.4 2.7 16 Cirrh/PHT Normal Normal Normal 
86 Fathima 58/F 90 110 80 90 7.8 0.9 2 39 Cirrh/PHT Cardiomegaly Old IWMI LV Dyfunction (Diastolic) 
87 Karthikeyan 25/M 86 120 70 86 7 1.4 3.4 32 Cirrh/PHT Normal Normal Normal 
88 Shanthi 47/F 94 120 80 94 9.2 1 2.3 34 Cirrh/PHT Cardiomegaly Ishaemic Changes  Normal 
89 Savithri 43/F 88 110 70 83 6.8 1.4 3.3 41 Cirrh/PHT Normal Normal Normal 
  
6 
90 Kuppan 50/M 98 120 70 86 8 3.4 2.7 28 Cirrh/PHT Normal Low voltage complex Pulmonary Hypertension  
91 Vetrivel 47/M 80 110 80 90 9.2 1.2 3.2 24 Cirrh/PHT Normal Low voltage complex Normal 
92 Gandhimathy 50/F 82 130 80 96 8.2 1.4 2.7 17 Cirrh/PHT Hydrothorax Normal Pericardial effusion 
93 Parthiban 45/M 80 110 80 90 5.6 2.6 3 43 Cirrh/PHT Normal Normal Normal 
94 Ellamma 41/F 92 110 70 84 8.6 0.8 2.7 21 Cirrh/PHT Normal Ishaemic Changes  Normal 
95 Jamuna 52/F 80 140 70 84 8 0.8 3.5 33 Cirrh/PHT Normal Low voltage complex Normal 
96 Vivek 55/M 86 110 80 90 4 0.8 2.8 38 Cirrh/PHT Cardiomegaly Normal Hyperdynamic flow 
97 Kasi 42/M 80 110 70 84 8.6 1 4 19 Cirrh/PHT Normal Normal Normal 
98 Mariyappan 52/M 98 100 80 86 6.4 1.6 2.8 23 Cirrh/PHT Normal Low voltage complex Normal 
99 Arivazhagan 51/M 88 110 70 84 9.4 0.6 2.3 40 Cirrh/PHT Cardiomegaly Ishaemic Changes  Normal 
100 Kalpana 40/F 94 110 80 90 9.8 4 3 21 Cirrh/PHT Normal Normal Normal 
 
 
